Skip to main content
Smart Investors Daily
Cumberland Pharmaceuticals Inc. logo

NASDAQ · CPIX

Cumberland Pharmaceuticals Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$6.98

Up+$0.10 (+1.43%)

Updated Oct 9, 2026, 3:11 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
37.02M
P/E ratio
-11.12
Dividend yield
42.98%
52-week range
$1.85 – $9.28
Volume
50.28K
Avg. volume
54.96K

Price performance · CPIX

CPIX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

CPIX closed at $6.98 after 21 trading sessions, up 7.72% for the selected period.

Last close
$6.98
Period change
+7.72%
Period low
$6.39
Period high
$8.20
Daily close
View OHLC price history
CPIX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$6.85$7.07$6.31$6.9850.28K
Oct 7, 2026$7.01$7.22$6.845$6.8924.6K
Oct 6, 2026$7.06$7.275$7.02$7.1422.58K
Oct 5, 2026$7.35$7.35$6.84$7.0957.06K
Oct 2, 2026$7.57$7.74$7.28$7.3922.63K
Oct 1, 2026$7.90$8.1401$7.26$7.5173.34K
Sep 30, 2026$7.75$8.035$7.61$7.839.96K
Sep 29, 2026$7.78$7.895$7.5988$7.658.93K
Sep 28, 2026$7.61$7.87$7.5606$7.7230.31K
Sep 25, 2026$8.06$8.06$7.48$7.6146.96K
Sep 24, 2026$7.93$8.29$7.75$8.0148.77K
Sep 23, 2026$8.07$8.34$7.72$7.9476.22K
Sep 22, 2026$7.50$8.3499$7.50$8.2070.53K
Sep 21, 2026$7.42$7.59$7.09$7.5933.59K
Sep 18, 2026$7.19$7.34$7.02$7.3227.65K
Sep 17, 2026$7.11$7.51$7.055$7.1970.59K
Sep 16, 2026$6.68$7.1089$6.61$6.9893.8K
Sep 15, 2026$6.67$6.74$6.49$6.6426.89K
Sep 14, 2026$6.38$6.74$6.365$6.7022.06K
Sep 11, 2026$6.61$6.75$6.38$6.3916.65K
Sep 10, 2026$6.25$6.505$6.24$6.4841.27K

Latest CPIX news

The latest Smart Investors Daily articles mentioning CPIX.

CPIX research

Overview

Company profile and research snapshot.

Company profile

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CPIX recent ratings
DateFirmRatingTarget
Dec 3, 2019B. RileyBuy—
Nov 18, 2019B. Riley FBRBuy—
Aug 17, 2018B. Riley FBRBuy—
Apr 17, 2018B. Riley FBRBuy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.